TSHA Taysha Gene Therapies, Inc.

NASDAQ
$5.02

Taysha Gene Therapies, Inc. (TSHA) Insider Activity

What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.

30D 90D 6M 1Y
Insider signal In line Selling ran in line with TSHA's own trailing one-year pace, with 46% of sale value under a prearranged plan.
Cluster activity 0 buyers in the last 30 days 0 buyers in the last 90 days 1 seller in the last 90 days
Insiders buying
0
0 transactions
Insiders selling
3
12 transactions
Purchases
$0
0 shares
Sales
$6.7M
1,368,795 shares
Net activity
-$6.7M
purchases less sales

How much of that selling was preplanned? 46% planned / 54% discretionary

10b5-1 plan sales $3.1M 3 transactions · 600,000 shares
Discretionary sales $3.6M 9 transactions · 768,795 shares

Largest single sale: $1.2M.

Where they traded

Buy Sell Dot area is proportional to transaction value.

No open-market insider purchase on record.

Recent open-market activity

Date Insider Role Action Shares Price Value Held after
Nagendran Sukumar President and Head of R&D Sell 10b5-1 200,000 $6.24 $1.2M 936,410 −17.6% of holding
Nagendran Sukumar President and Head of R&D Sell 10b5-1 200,000 $4.46 $892.0K 1,136,410 −15% of holding
Alam Kamran CHIEF FINANCIAL OFFICER Sell 1,655 $4.52 $7.5K 1,442,131 −0.1% of holding
Nolan Sean P. Chief Executive Officer Sell 41,312 $4.61 $190.4K 2,908,257 −1.4% of holding
Nagendran Sukumar President and Head of R&D Sell 26,918 $4.61 $124.1K 1,317,389 −2% of holding
Alam Kamran CHIEF FINANCIAL OFFICER Sell 23,849 $4.61 $109.9K 1,443,786 −1.6% of holding
Nolan Sean P. Chief Executive Officer Sell 136,789 $4.75 $649.7K 2,949,569 −4.4% of holding
Nagendran Sukumar President and Head of R&D Sell 89,132 $4.75 $423.4K 1,344,307 −6.2% of holding
Alam Kamran CHIEF FINANCIAL OFFICER Sell 78,968 $4.75 $375.1K 1,467,635 −5.1% of holding
Nagendran Sukumar President and Head of R&D Sell 10b5-1 200,000 $4.71 $942.0K 1,006,439 −16.6% of holding
Nagendran Sukumar President and Head of R&D Sell 260,047 $4.51 $1.2M 1,006,439 −20.5% of holding
Nagendran Sukumar President and Head of R&D Sell 110,125 $4.75 $523.1K 1,006,439 −9.9% of holding

Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.